Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
Decision Diagnostics bills itself as a leading manufacturer and worldwide distributor of diabetic test strips. The company’s products are designed to operate efficiently in certain glucose meters worldwide. Similarly, the company has, in the recent past, diversified its footprint with the development of kits for testing of the coronavirus.
Why is Decision Diagnostics Exploding?
OTCMKTS:DECN has taken the market by storm on unveiling a new screening methodology for the coronavirus. The new test kit is designed to provide a timely, simple to use, and cost-effective solution for the screening of the COVID-19 virus. The introduction of the test kit comes at a time of growing demand for more effective ways of testing for the virus to curb the further spread.
Decision Diagnostics is planning to make the kits available t in pharmacies as well as doctors’ offices, clinics, and urgent care centers. The company projecting the sale of up to 420 million kits in the first full year of sale is the latest development that has caught the market by surprise.
Should the company succeed in selling 420 million kits, and then it stands a fair chance of generating significant returns that should go a long way in bolstering its bottom line.
“GenViro! Will be a perfect storm product, and our timing here is spot-on. Our biggest challenge will be meeting the expected crushing demand. For that we prepared, and are interviewing most likely partners currently,” said Chief Executive Officer, Keith Berman.
OTCMKTS:DECN has also introduced GenExpidient Universal Translator that is to be included in the Covid-19 test kit. The device will make it easy to clean and disinfect the coronavirus test kit GenViro meter.
The company is to sell the coronavirus test kits at between $4.95 and $7.95. A confirmation that the company has already been contacted by a number of potential partners to supply the test kit underscores the strong demand in the market. The company is exploring the possibility of partnering another company in a bid to enhance the distribution of the test kit and be able to generate the desired returns.
In addition to the coronavirus test kit, the company also boasts of a diversified product portfolio that continues to strengthen its revenue base. For starters, it is currently marketing the PetSure test strip designed for diabetic testing in dogs and cats.
With the spread of the coronavirus showing no signs of slowing down, Decision diagnostics has on its hands a huge opportunity. Demand for coronavirus test kit should continue to spike as governments around the world race against time to contain the pandemic.
Likewise, companies with products able to enable the testing stand to reap big until an ideal vaccine for the virus comes into being. That said, Decision Diagnostics should be able to generate significant returns on selling more than 1 million GenViro test kit.
Similarly, the stock looks set to continue powering higher as investors come to terms with the huge opportunity up for grabs.
We will be updating our subscribers as soon as we know more. For the latest updates on OTCMKTS:DECN, sign up below!
Disclosure: We have no position in OTCMKTS:DECN and have not been compensated for this article.
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140)…
Rainmaker Worldwide Inc (OTCMKTS:RAKR) Looking For Bagholders
On the OTC Markets, there are a lot of pump and dumps. Investors need to protect themselves from these types of scams and one, in particular, is Rainmaker Worldwide Inc (OTCMKTS:RAKR).
OTCMKTS:RAKR Price Action
While the price action recently has been positive, it’s just a matter of time before RAKR is trading in the double zeros again. It’s not a question of if it will happen, but when it will happen.
About Rainmaker Worldwide
According to its profile, Rainmaker Worldwide Inc. is headquartered in Peterborough, Canada, with an innovation and manufacturing center in Rotterdam, Netherlands. Its patented water technology provides economical drinking water wherever it’s needed and at scale. Rainmaker builds two types of energy-efficient, fresh water-producing technologies to participate in this opportunity. 1. Air-to-Water, which harvests fresh water from humidity in the atmosphere. 2. Water-to-Water, which transforms seawater or polluted water into drinking water.
Lack of Fundamentals
The biggest concern facing investors is the lack of fundamentals. OTCMKTS:RAKR has a current market cap of $41 milli0n, but reported just $1000 in sales in the quarter ending September 30, 2019. Making matters worse is that Rainmaker burned through $524,000 in the quarter. Throughout its history, Rainmaker has lost $14.7 million.
EU Horizon 2020 Project and $2.5 million grant
Last September, Rainmaker touted the award of the European Union (EU) Horizon 2020 Project for Rainmaker’s Water to Water Product. According to the press…
Why Lexaria Bioscience Corp (OTCMKTS:LXRP) Is A Comeback Play
Lexaria Bioscience Corp (OTCMKTS:LXRP) brightest days lie ahead. The sentiments shared by Chief Executive Officer, Chris Bunka, are slowly coming to fruition, going by recent price action activity. After a steep pullback in 2019, the stock has once again started climbing higher, as investors react to milestones achieved in 2019 that affirm long-term prospects.
Lexaria Bioscience Catalysts and Price Analysis
A confirmation that the global innovator in drug delivery systems achieved almost everything it set out to accomplish in 2019 continues to strengthen market sentiments. The inking of strategic partnerships with Fortune 500 style companies is another development that the management continues to tout.
Likewise, Lexaria Bioscience succeeded in getting its DehydraTECH technology to market, consequently creating an avenue for generating long-term value. The company’s Intellectual Property strategy has also started to pay dividends, affirming what is at stake going forward. Reports that the company is already experiencing an increase in revenues is another catalyst that continues to shore the stock’s sentiments and prospects in the markets.
Lexaria Bioscience has already started bottoming out from all-time lows in what appears to be the development of a positive trend. A 10% plus rally from one-year lows continue to fuel optimism that the stock has clocked a bottom and due for a correction higher.
Standing in the way of the emerging uptrend is the $0.50 mark, which is the immediate short-term resistance level. A rally followed by a close above the…